Skip to main content
PLOS Pathogens logoLink to PLOS Pathogens
. 2021 Jul 28;17(7):e1008911. doi: 10.1371/journal.ppat.1008911

Host immunity increases Mycobacterium tuberculosis reliance on cytochrome bd oxidase

Yi Cai 1,#, Eleni Jaecklein 2,#, Jared S Mackenzie 3, Kadamba Papavinasasundaram 2, Andrew J Olive 4, Xinchun Chen 1, Adrie J C Steyn 3, Christopher M Sassetti 2,*
Editor: Helena Ingrid Boshoff5
PMCID: PMC8351954  PMID: 34320028

Abstract

In order to sustain a persistent infection, Mycobacterium tuberculosis (Mtb) must adapt to a changing environment that is shaped by the developing immune response. This necessity to adapt is evident in the flexibility of many aspects of Mtb metabolism, including a respiratory chain that consists of two distinct terminal cytochrome oxidase complexes. Under the conditions tested thus far, the bc1/aa3 complex appears to play a dominant role, while the alternative bd oxidase is largely redundant. However, the presence of two terminal oxidases in this obligate pathogen implies that respiratory requirements might change during infection. We report that the cytochrome bd oxidase is specifically required for resisting the adaptive immune response. While the bd oxidase was dispensable for growth in resting macrophages and the establishment of infection in mice, this complex was necessary for optimal fitness after the initiation of adaptive immunity. This requirement was dependent on lymphocyte-derived interferon gamma (IFNγ), but did not involve nitrogen and oxygen radicals that are known to inhibit respiration in other contexts. Instead, we found that ΔcydA mutants were hypersusceptible to the low pH encountered in IFNγ-activated macrophages. Unlike wild type Mtb, cytochrome bd-deficient bacteria were unable to sustain a maximal oxygen consumption rate (OCR) at low pH, indicating that the remaining cytochrome bc1/aa3 complex is preferentially inhibited under acidic conditions. Consistent with this model, the potency of the cytochrome bc1/aa3 inhibitor, Q203, is dramatically enhanced at low pH. This work identifies a critical interaction between host immunity and pathogen respiration that influences both the progression of the infection and the efficacy of potential new TB drugs.

Author summary

Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is a serious global health problem that is responsible for over one million deaths annually, more than any other single infectious agent. In the host, Mtb can adapt to a wide variety of immunological and environmental pressures which is integral to its success as a pathogen. Accordingly, the respiratory capacity of Mtb is flexible. The electron transport chain of Mtb has two terminal oxidases, the cytochrome bc1/aa3 super complex and cytochrome bd, that contribute to the proton motive force and subsequent production of energy in the form of ATP. The bc1/aa3 super complex is required for optimal growth during infection but the role of cytochrome bd is unclear. Here we report that the cytochrome bd oxidase is required for resisting the adaptive immune response, in particular, acidification of the phagosome induced by lymphocyte-derived IFNγ. We found that the cytochrome bd oxidase is specifically required under acidic conditions, where the bc1/aa3 complex is preferentially inhibited. Additionally, we show that acidic conditions increased the potency of Q203, a cytochrome bc1/aa3 inhibitor and candidate tuberculosis therapy. This work defines a new link between the host immune response and the respiratory requirements of Mtb that affects the potency of a potential new therapeutic.

Introduction

Tuberculosis (TB) is responsible for an estimated 1.4 million deaths annually and remains one of the most deadly infectious diseases [1]. The causative agent of TB, Mycobacterium tuberculosis (Mtb), is an obligate aerobe and relies on oxidative phosphorylation (OXPHOS) via the electron transport chain (ETC) and glycolysis for energy production. The mycobacterial ETC has two terminal oxidases, the cytochrome bc1/aa3 super complex that is related to mitochondrial complex III and IV, and the cytochrome bd oxidase which is unique to prokaryotes. These terminal oxidases transfer electrons from the ETC to O2 and contribute to the proton motive force (PMF) gradient that powers the production of ATP by ATP synthase. Both genetic [2] and chemical inhibition of the cytochrome bc1/aa3 [35] has been used to show that this complex is required for optimal growth and persistence during infection, and cytochrome bc1/aa3 inhibitors are under evaluation as antimycobacterial therapies [6].

In the absence of cytochrome bc1/aa3, electrons are rerouted through the cytochrome bd oxidase [7]. The latter complex in Mtb is encoded in a single operon, cydABDC, which produces both the cydAB oxidase complex and cydDC, a putative ABC-transporter that has not been studied in Mtb, but is necessary for assembly of the cytochrome in Escherichia coli [8,9]. Genetic deletion of the cydABDC operon produces hyper-susceptibility to cytochrome bc1/aa3 inhibitors, demonstrating a partially-redundant role for the terminal oxidases [4,7,10]. However, the specific role played by the cytochrome bd oxidase in Mtb remains unclear. In E.coli, the cytochrome bd oxidase detoxifies peroxide radicals and maintains respiration under hypoxic conditions [11,12]. Similar observations in the saprophyte, Mycobacterium smegmatis, show that cyd mutants are hyper-susceptible to peroxide stress and expression of the cydAB operon is induced in hypoxic conditions [1315]. In addition, a transposon mutant screen predicted that the cydABDC operon is required for optimal Mtb growth at pH 4.5, suggesting additional functions [16]. While it is plausible that these properties contribute to Mtb fitness during infection, the role played by the cytochrome bd oxidase in the mouse model of TB remains unclear. Some studies report no effect of cydABDC mutation, while others describe a fitness defect at the later stages of infection [2,4,17]. Thus, while it is clear that the cytochrome bd oxidase is active in mycobacteria, the non-redundant role of this system during infection is unknown.

As an obligate aerobe it is likely that Mtb’s flexible respiratory chain has evolved to adapt to the changing environment encountered during infection. During the initial days after infection of the lung, Mtb replicates in macrophages, but once these cells are stimulated by T cell-derived cytokines, they restrict Mtb growth. The stressors associated with activation of the macrophage cause a number of specific alterations in the bacterial environment that may alter respiratory requirements. In particular, IFNγ induces antimicrobial responses in the macrophage, including the production of the known respiratory poison, nitric oxide (NO) [18] via nitric oxidase synthase 2 (NOS2). Additionally, IFNγ induces superoxide production via the NADPH-dependent phagocyte oxidase (Phox), which alters the respiratory requirements of another intracellular pathogen, Salmonella enterica [19]. Lastly, IFNγ promotes the maturation of the pathogen-containing vacuole, promoting both its acidification and fusion with more degradative compartments. The observation that cydAB expression peaks with the onset of the adaptive immune response in the mouse model of infection further suggests an association between T cell cytokines, such as IFNγ, and alterations in the respiratory requirements of Mtb [17].

In this work, we investigated the interactions between macrophage activation and the mycobacterial respiratory chain. We report that cytochrome bd oxidase is specifically required for the bacillus to resist IFNγ-induced macrophage function. In particular, cytochrome bd oxidase is necessary in acidic environments similar to those encountered in the phagosome of IFNγ activated macrophages. These compartments can reach pH levels as low as 4.5 [20,21], which we show preferentially inhibits the function of the cytochrome bc1/aa3 complex. The relative acid-resistance of the cytochrome bd oxidase explains its role in counteracting IFNγ-dependent immunity, and suggests important interactions between immunity and respiratory chain inhibitors that are in clinical development as TB therapeutics.

Results

ΔcydA mutant is susceptible to IFNγ-activation of macrophages independent of NOS2 and Phox

To investigate the effects of macrophage activation state on the requirement for the cytochrome bd oxidase in Mtb, we constructed a ΔcydA deletion mutant in H37Rv [22]. Consistent with previous studies, there was no difference in growth between H37Rv and ΔcydA mutants in broth culture [2,10] (Fig 1A). We compared the fitness of H37Rv and ΔcydA mutants in bone marrow-derived macrophages (BMDMs) from C57BL/6J (wildtype) mice. Initially, we used flow cytometry and fluorescent live/dead reporter strains of Mtb to estimate relative bacterial growth and viability. The Mtb strains expressed a constitutive GFP marker and an anhydrotetracycline (ATc)-inducible RFP marker. GFP intensity was used to estimate total infected cell number and ATc-induced RFP intensity served as a surrogate measure of the relative viability of the bacterial population in each infected macrophage, and has been show to correlate with CFU in this setting [23]. By these metrics, the growth and viability of H37Rv and the ΔcydA mutant were not appreciably different in unstimulated BMDMs (Fig 1B).

Fig 1. CydA is required to resist IFNγ-mediate immunity independent of NOS2 and Phox.

Fig 1

A) Growth of H37Rv and ΔcydA in 7H9 broth over 12 days in 96 well plates. B) C57BL/6J (WT), Nos2−/− and Cybb−/− BMDMs were left untreated or treated with 25ng/mL of IFNγ for 18 h. Macrophages were infected with H37Rv (solid) or ΔcydA (diagonal bars) live-dead reporter strains (MOI = 5). Y-axis represents the fraction BMDMs with live bacteria (RFP+GFP+) over total infected BMDMs (GFP+) determined by flow cytometry at 4 days post-infection. C) IFNγ treated or untreated BMDMs were infected (MOI = 5) with H37Rv (solid) or ΔcydA (diagonal bars). CFU determined 4 days post-infection. Data were normalized using the following formula, [sample value]/[mean of untreated]*100, error bars reflect the normalized values. Mean of untreated for H37Rv in WT, Nos2−/−, and Cybb−/− BMDMs: 9.9x104, 1.28x105, and 8.5x104 CFU/mL, respectively. Mean of untreated for ΔcydA in WT, Nos2−/−, and Cybb−/− BMDMs: 4.7x104, 1.0x105, and 7.45x104 CFU/mL, respectively. D) IFNγ treated or untreated Nos2−/− BMDMs infected with the indicated strains (MOI = 5). CFU determined 4 days post-infection. Represented as percent survival relative to untreated, as in panel C. Mean of untreated for H37Rv 4.1x104 CFU/mL, ΔcydA 3.7 x104 CFU/mL, ΔcydA::cydA 4.0 x104 CFU/mL, and ΔcydA::cydABDC 3.1 x104 CFU/mL. Analysis of B-D was preformed using one-way ANOVA with Sidak post-test to correct for multiple comparisons. * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, **** p-value <0.0001. Data depict single experiments that are representative of at least 2 independent studies.

In other bacterial systems, the cytochrome bd oxidase is important for resistance to NO and oxidative stress, which are major mediators of IFNγ-dependent antimicrobial activity [11,2426]. To determine if IFNγ or these reactive species alter the requirement for ΔcydA, we stimulated BMDMs with IFNγ, and included cells from Nos2−/− and Cybb−/− mice which lack functional NOS2 and Phox systems, respectively. In wildtype BMDMs, addition of IFNγ significantly reduced the number of cells harboring live H37Rv and ΔcydA bacteria (Fig 1B). IFNγ treatment had no effect on the viability of H37Rv in Nos2−/− BMDMs, indicating that IFNγ-mediated inhibition of H37Rv is primarily dependent on NO, consistent with previous studies [21,25] (Fig 1B). In contrast, NOS2 and CYBB were not necessary for IFNγ to inhibit ΔcydA mutants (Fig 1B).

These observations were confirmed by CFU enumeration (Fig 1C). The magnitude of IFNγ-dependent inhibition was smaller in the CFU assay than the flow cytometry study, likely reflecting increased sensitivity of the live/dead reporter for bacterial fitness. Regardless, the CFU assay also showed that IFNγ treatment reduced the viability of H37Rv in a Nos2-dependent, Cybb-independent manner, whereas the suppression of ΔcydA mutants was independent of both mediators. This ΔcydA mutant phenotype could be complemented in trans by expressing the cydABDC operon but not ΔcydA alone (Fig 1D). These observations indicated the entire cydABDC operon was necessary to resist an IFNγ-induced stress that is independent of NOS2 and CYBB.

IFNγ but not iNOS or Phox is necessary for the attenuation of ΔcydA in mouse lungs

The interaction between IFNγ and ΔcydA was then assessed in the mouse model. To evaluate the relative fitness of the ΔcydA mutant, we performed competitive infections using a mixture of H37Rv::Kan and ΔcydA::Hyg. To test the importance of lymphocyte-derived IFNγ, the relative fitness of the ΔcydA mutant was assessed in wild type C57BL/6J mice and animals lacking adaptive immunity (Rag2−/−), IFNγ receptor (Ifngr1−/−), NOS2 (Nos2−/−) and Phox (Cybb−/−) (Fig 2A). At each timepoint, lung homogenates were plated on kanamycin and hygromycin and CFU were enumerated to compare the fitness of H37Rv and ΔcydA (Fig 2B). Day 1 CFU showed equivalent numbers of H37Rv and ΔcydA bacteria in the lung (Fig 2C). On day 15 post infection, before the onset of adaptive immunity, there was no significant difference in CFU between H37Rv and ΔcydA across all five mouse genotypes (Fig 2B). Once the adaptive response was established after 30 days of infection, we observed a significant decrease in ΔcydA lung CFU compared to H37Rv in wildtype, Nos2−/−, and Cybb −/− mice. However, there was no difference between ΔcydA and H37Rv lung CFU in Ifngr1−/− and Rag2−/− mice demonstrating that the attenuation of the ΔcydA strain is dependent on lymphocytes and IFNγ (Fig 2B). Complementation of the ΔcydA mutant with cydABDC rescued the fitness defect observed in the mutants at the 30-day timepoint in wildtype mice (Fig 2C). These observations were consistent with the ex vivo macrophage infections, both indicating that the IFNγ-dependent attenuation of ΔcydA is NOS2 and Phox independent.

Fig 2. CydA is required for persistence in IFNγ competent mice independent of Nos2 or Phox.

Fig 2

A) Schematic of experimental design for 1:1 co-infection with H37Rv::Kan and ΔcydA::Hyg. Lungs were collected on day 15 and day 30 post infection and dilutions of lung homogenates were plated on both 7H10+kanamycin and 7H10+hygromycin. B) CFU of H37Rv (black) and ΔcydA (open) in the lungs of C57BL/6J (WT), Nos2−/−, Cybb−/−, Ifngr1−/−, and Rag2−/− mice were enumerated at day 15 and day 30 post-infection. C) Day 1 H37Rv and ΔcydA CFU from C57BL/6J mice. D). Lung CFU of H37Rv and the complemented mutant strain (ΔcydA::ABDC) shown at day 15 and day 30 post-infection. All comparisons assessed using paired t-test. * p-value < 0.05. Data depict single experiment that is representative of at least 2 independent studies.

ΔcydA mutants are defective for growth at low pH

Beyond stimulating the production of RNS and ROS in macrophages, IFNγ also promotes the maturation and acidification of the mycobacterial phagosome. An in vitro transposon mutant screen suggested that the cydABDC operon may contribute to optimal Mtb growth at pH 4.5 [16]. To determine if the hyper-susceptibility of ΔcydA to IFNγ could be due to phagosomal maturation and acidification, we investigated the fitness of ΔcydA mutants under acidic conditions. 7H9 media was adjusted to pH values that span those encountered in the maturing phagosome [20,21] using citrate-phosphate buffer, as described [27,28]. Using a multi-well plate assay, we found that the growth rate of ΔcydA was significantly reduced at low pH in comparison to H37Rv (Fig 3A and 3B). However, we also observed that the ΔcydA mutant grew modestly faster than H37Rv at pH 7.4 in this static assay format. To ensure equal aeration of these cultures, we also conducted growth studies in agitated cultures using with H37Rv, ΔcydA and the complemented strain. In this assay format, we again observed that the growth of ΔcydA was significantly attenuated at pH 6.2 compared to either the parental H37Rv strain or the complemented mutant (ΔcydA::cydABDC) (Fig 3C).

Fig 3. CydA is required for growth in acidic conditions.

Fig 3

A) Growth of H37Rv and ΔcydA in 7H9-tyloxapol at pH 7.4, pH 6.0, pH 5.5, pH 5.0, and pH 4.5 measured by OD600 for 5 days in a 96 well plate. B) Growth rate (GR) for the samples in panel A, relative to pH 7.4. GR was calculated between days 0 and 4, when the increase in OD was linear. C) Growth of H37Rv, ΔcydA, and ΔcydA::ABDC in 7H9-Tyloxapol at pH 7.0, pH 6.2, measured by OD600 for 6 days in aerated (i.e.agitated) cultures. D) WT, Nos2−/− and Cybb−/− BMDMs were left untreated or treated with IFNγ (25ng/mL). Macrophages were infected with H37Rv (solid) or ΔcydA (diagonal bars) live-dead reporter strains (MOI = 5). Post-infection BMDMs were left untreated, treated with IFNγ, or treated with IFNγ and Bafilomycin A (100ng/mL). The fraction of macrophages harboring live bacteria (%Live/ Live+Dead) was determined using flow cytometry. Analysis of B-D was performed using a one-way ANOVA with Sidak post-test to correct for multiple comparisons. * p-value < 0.05, ** p-value < 0.01, **** p-value <0.0001. Data depict single experiments that are representative of at least 2 independent studies for macrophage infections and 3 independent studies for in vitro experiments.

We next sought to determine if the IFNγ-dependent acidification of the phagosome in macrophages could account for the intracellular growth defect of the ΔcydA mutant. BMDMs from wildtype, Nos2−/− and Cybb−/− mice were infected with either H37Rv or the ΔcydA mutant, and we determined if the inhibitory effect of IFNγ was altered by bafilomycin A1, an inhibitor of the vacuolar-type H+-ATPase that is responsible for the acidification and maturation of the phagosome. Using the live/dead reporter as a surrogate for bacterial fitness, we confirmed that NOS2 was required for IFNγ to inhibit H37Rv, but not the ΔcydA mutant, providing a situation where the NO-independent inhibitory effect of IFNγ on bd oxidase-deficient Mtb could be assessed. In these Nos2−/− macrophages, BAF had no effect on the fitness of H37Rv, but completely reversed the inhibitory effect of IFNγ on the ΔcydA mutant, restoring fitness to levels equivalent to unstimulated BMDMs (Fig 3D). In all three macrophage genotypes, BAF treatment restored the fitness of the ΔcydA mutant to wild type levels in the presence of IFNγ. While BAF treatment had a modest effect on the fitness of wild type Mtb, the preferential effect on the ΔcydA mutant was consistent with the hypersensitivity of this strain to low pH. Together these observations indicate that the NO-independent inhibitory effect of IFNγ on bd oxidase-deficient Mtb could primarily be attributed to the environment encountered in the mature acidified phagosome.

The bd oxidase is necessary for optimal respiration under low pH conditions

The fitness defect of CydA-deficient bacteria in acidic pH suggested that under this condition, bd oxidase activity was increased, bc1/aa3 activity was decreased, or both. To investigate these possibilities, we used extracellular flux analysis (Agilent Seahorse XFe96) to measure oxygen consumption rate (OCR). We first optimized conditions to independently assess the activity of the two respiratory complexes. Treatment of WT H37Rv or the complemented ΔcydA::cydABDC strain with the cytochrome bc1/aa3-inhibitor, Q203 [5], led to a paradoxical increase in OCR (Fig 4A), which has been previously attributed to increased bd oxidase activity [7,10]. We confirmed this interpretation by finding that the Q203 treatment of the ΔcydA mutant virtually abolished OCR (Fig 4A). Thus, our Q203 treatment effectively inhibited bc1/aa3 and the OCR detected under these conditions solely reflected bd oxidase activity.

Fig 4. The bd oxidase is necessary for optimal respiration under low pH conditions.

Fig 4

Oxygen consumption rate (OCR) was measured using the extracellular flux analyser. A) H37Rv, ΔcydA and ΔcydA::ABDC strains were exposed to media at pH 7.4 for ~30 minutes and then treated with Q203 (10nm) at the indicated time. Data are normalized to point 4. Bar graph of point 9 (black arrow). B) H37Rv was exposed to media at pH 7.4 and pH 4.5 for ~30 minutes and then treated with media, Q203 (300x MIC50 900nM), or BDQ (300x MIC50 16.2uM) followed by the uncoupler, CCCP, at the indicated times. Data are normalized to point 4. Bar graphs are plotted from point 5 and point 9 (black arrows in A) after the addition of BDQ/Q203 and before the addition of CCCP, respectively. C) OCR measurements (pmol O2/min) of H37Rv, ΔcydA and ΔcydA::ABDC strains after ~30 minutes pre-exposure to media at pH 7.4 or pH 4.5. Bar graphs are plotted from point 4 (black arrow). Analysis was performed using a one-way ANOVA with Tukey post-test. * p-value < 0.05, ** p-value < 0.01, **** p-value <0.0001. Data depict single experiments that are representative of at least 2 independent studies.

We next tested the effect of pH on each of the bd- and bc1/aa3-complexes. To interrogate the bd oxidase, we preadapted H37Rv to pH 7.4 or 4.5 and measured OCR during bc1/aa3 inhibition with Q203. We found that low pH accentuated bd oxidase-dependent OCR under this condition (Fig 4B). Treatment of H37Rv with the ATP synthase inhibitor, bedaquiline (BDQ) also lead to an expected increase in OCR [7], and was transiently enhanced by low pH (Fig 4B). To assess the effect of pH on the bc1/aa3 complex, we compared the OCR of H37Rv and ΔcydA strains. Preadaptation to pH 7.4 or 4.5 produced a steady-state OCR that was consistent over 25 minutes of monitoring. pH had little effect on the OCR of H37Rv or the ΔcydA::cydABDC strains, in which both respiratory complexes are functioning. In contrast, OCR of the ΔcydA mutant that exclusively depends on the bc1/aa3 system was markedly inhibited at pH 4.5 (Fig 4C). Thus, the bd oxidase is functional, and even operates at increased levels, at acidic pH; whereas the bc1/aa3 is inhibited under these conditions.

Q203 is bactericidal at low pH

Given this pH-dependent decrease in bc1/aa3 activity, we hypothesized that acid stress would also increase the sensitivity of this complex to chemical inhibition. Indeed, reducing the pH from 7.4 to 5.5 enhanced the potency of Q203, lowering the IC50 by almost 20-fold (Fig 5A). While Q203 has been found to be bacteriostatic at neutral pH in vitro[29], we determined if the increased potency Q203 at low pH also produced bactericidal activity. H37Rv was grown at pH 7, pH 6.2, or pH 5.7 in the presence or absence of Q203 at 30x the MIC50 for 6 days. Mtb viability was assessed by CFU at day 0, day 3, and day 6. At pH 7 and pH 6.2 Q203 showed the expected bacteriostatic effect, and no decrease in CFU was apparent in treated cultures (Fig 5B). However, at pH 5.7 we observed robust bactericidal activity for Q203, resulting in a 10-fold decrease in CFU by day 3 of treatment, and more than a 1,000-fold decrease by day 6 (Fig 5B). Thus, acidic pH has a dramatic effect on Q203 activity, both lowering its MIC and promoting cell death.

Fig 5. Low pH increases the potency of Q203.

Fig 5

A) IC50 curves of H37Rv treated with Q203 at pH 7.0, pH 6.5 and pH 5.5 for 6 days in agitated culture. IC50 values for Q203 (nM) at each pH shown in the table. OD600 values are represented as relative to the no drug conditions because H37Rv growth is attenuated at pH 5.5. B) Day 0, 3, 6 CFU of H37Rv grown in agitated culture over 6 days at pH 7.0, 6.2, and pH 5.7 in the presence of 30x MIC Q203 (90 nM) or vehicle control (DMSO). Day 0 CFU timepoint is shared across all groups from DMSO pH 7 condition. Analysis was performed using a one-way ANOVA with Tukey post-test. ** p-value < 0.01, **** p-value <0.0001. Data depict single experiments that are representative of at least 3 independent studies.

Discussion

The flexibility of bacterial respiratory chains facilitates adaptation to changing environments, and in many situations the bd oxidase becomes critical under conditions where the bc1/aa3 complex is inhibited. In pathogens such as E.coli, Listeria monocytogenes, and Salmonella typhimuirium, the requirement for the cytochrome bd oxidase in bacterial virulence has been attributed to its role in resisting hypoxia and nitrosative and oxidative stress [26,3032]. While previous studies in M. marinum and M. smegmatis found that the mycobacterial bd oxidase can also confer resistance to hypoxia and peroxide, the specific roles played by the cytochrome bd and bc1/aa3 oxidases of Mtb during infection has been less clear. Our work indicates that the flexibility of the Mtb respiratory chain facilitates adaptation to changes in the immune response. As outlined below, our findings specifically suggest that the cytochrome bd oxidase provides resistance to IFNγ-mediated immunity by facilitating respiration under the acidic conditions encountered in the phagosomes of IFNγ-stimulated macrophages.

In both ex vivo macrophage cultures and intact animals, we found that the bd oxidase was required to resist IFNγ-dependent immunity. These data are consistent with those of Shi et al., who showed that Mtb cytochrome bd oxidase mutants were specifically attenuated in C57BL6 mice only after 50 days of infection. [17]. Conversely, other studies have concluded that the cytochrome bd oxidase is dispensable for growth in C57BL/6J and BALB/C mice [2,4,33]. Dhar & McKinney found that cydC is dispensable for growth in C57BL/6 mice but cydC mutants are attenuated during INH treatment in an IFNγ-dependent manner [33]. We suspect that these differing conclusions were caused by variations in the infection models. Specifically, our study used a competitive infection, which ensures that both wild type and mutant bacteria are exposed to identical immune pressures and captures even transient differences in fitness. As a result, competitive studies, such as ours, are a particularly sensitive approach to detect differences in fitness. While it is possible that another animal model or an extended infection period would discover a more pronounced growth defect, even a small or transient difference in bacterial fitness reflects an evolutionary advantage that could be responsible for maintaining the cydABDC operon in the Mtb genome.

While IFNγ stimulation induces wide-spread transcriptional changes and antimycobacterial functions in macrophages, our data suggest that the bd oxidase requirement is related to phagosomal pH. NOS2 and Phox are strongly induced by IFNγ, and the requirement for the bd oxidase in other bacterial pathogens has been related to the resulting NO and ROS [24]. As a result, it was somewhat surprising that the sensitivity of ΔcydA mutant bacteria to IFNγ treatment was independent of these mediators. Instead, multiple lines of evidence indicated that this mutant was sensitive to the low pH encountered in the phagosome of IFNγ-stimulated macrophages. Firstly, we found that that bd oxidase-deficient bacteria grew poorly at low pH. These findings that are consistent with previous transposon mutant screening data suggesting that the cydABDC operon was required for optimal growth at pH 4.5 [16]. These in vitro growth defects were related to the intracellular growth environment by demonstrating that inhibition of vacuolar maturation and acidification with BAF abrogated the relative fitness difference between ΔcydA and wild type Mtb in IFNγ-stimulated macrophages. While these data are consistent with a primary role for the bd oxidase in adaptation to low pH conditions, we note that inhibition of phagosome acidification can have pleiotropic effects on processes such as phagosome-lysosome fusion and autophagy. Thus, while it remains possible that additional stresses play a role, our observations are consistent with a model in which the bd oxidase promotes resistance to the adaptive immune response by promoting respiration in the low pH environment of the IFNγ-stimulated macrophage.

While the requirement for bd oxidase activity at low pH can be attributed to the reduced activity we detected for the bc1/aa3 complex under these conditions, the mechanism by which low pH inhibits the activity of the cytochrome bc1/aa3 is unclear. The cytochrome bc1/aa3 super complex is tightly coupled to the transport of protons [34]. For every O2 molecule reduced by the super complex, 4 protons are pumped into the periplasm and contribute to the proton motive force (PMF) [34]. While the cytochrome bd oxidase also contributes protons to PMF, it only contributes half of the protons for every molecular oxygen reduced as the super complex [8,35]. It is possible that the tight coupling between proton pumping and electron transfer for the cytochrome bc1/aa3 complex results in its inhibition when extracellular proton concentrations are high. However, acid stress induces a wide variety of transcriptional and physiological responses in Mtb and it is also possible that pH has additional indirect effects on the cytochrome bc1/aa3 complex [3638].

The success of bedaquiline, a mycobacterial ATPase inhibitor, has made respiration an attractive target for new therapeutics. Multiple small molecule inhibitor screens have identified drugs that target the QcrB component of the proton-pumping cytochrome bc1/aa3 [3,5,39,40], most notably is Q203 (Telacebec) which is currently in clinical trials [5,6]. However, the flexibility of the mycobacterial respiratory chain has raised concerns about the potential efficacy of this drug [2,4,29,41]. One strategy to enhance the efficacy of respiratory inhibition is to simultaneously target both the bc1/aa3 and bd oxidase complexes, which produces a bactericidal effect [4,7,10]. Our data suggest that immunity is another important factor that determines the relative importance of terminal oxidases and the ultimate efficacy of these agents. The concept is similar to the previously described synergy between IFNγ-induced tryptophan depletion and the efficacy of Mtb tryptophan synthesis inhibitors [16]. These examples highlight the importance of understanding the interactions between bacterial physiology and immunity for evaluating and optimizing new therapies.

Experimental methods

Ethics statement

Animal work was approved by University of Massachusetts Medical School IACUC (protocol number 202000009). All protocols conform to the USDA Animal Welfare Act, institutional policies on the care and humane treatment of animals, and other applicable laws and regulations.

Bacterial growth and strain generation

Mycobacterium tuberculosis strains were cultured at 37°C in complete Middlebrook 7H9 medium containing oleic acid-albumin-dextrose-catalase (OADC, Becton, Dickinson), 0.2% glycerol, and 0.05% Tween80 or 0.02% Tyloxapol. Hygromycin, kanamycin, and zeocin were add as necessary at 50 ug/mL, 25 ug/mL, and 25 ug/mL, respectively. All Mtb mutant strains were derived from the wildtype H37Rv. cydA and cydABDC operon were deleted by allelic exchange as described previously [22]. The gene deletions were confirmed by PCR verification and sequencing of the 5’ and 3’ recombinant junctions and the absence of an internal fragment within the deleted region. An L5attP-zeoR-CydABDC-operon complementing plasmid was assembled by Gateway reaction (Invitrogen) and transformed into the ΔcydA::Hyg mutant to generate the ΔcydA::ABDC-complementing strain. The Live/Dead reporter strains were generated by transforming Mtb with the replicating Live/Dead plasmid that contains a constitutively expressed GFP and a tetracycline-inducible TagRFP fluorescent protein.

Mice

C57BL/6, Cybb−/−, Nos2−/−, Ifngr1−/− and Rag2−/− were purchased from the Jackson Laboratory. Housing and experimentation were in accordance with the guidelines set forth by the Department of Animal Medicine of University of Massachusetts Medical School and Institutional Animal Care and Use Committee. Animals used for experimentation were between 6 and 8 weeks old.

Mouse infections

Prior to infection, Mtb strains were resuspended and sonicated in PBS containing 0.05% Tween80. ΔcydA mutant fitness in vivo was determined by inoculating mice with a ~1:1 mixture of ΔcydA (hygromycin resistant) and H37Rv (harboring pJEB402 chromosomally integrated plasmid encoding kanamycin resistance) strains via the respiratory route using an aerosol generation device (Glas-Col). At the indicated time points, mice were sacrificed and CFU numbers in lung homogenate were determined by plating on 7H10 agar supplemented with OADC containing Kanamycin (25 ug/mL) or Hygromycin (50 ug/mL).

Macrophage infection

Bone marrow derived macrophages (BMDMs) were isolated from C57BL/6, Cybb−/− or Nos2−/− mice by culturing bone marrow cells in DMEM supplemented with 20% conditioned medium from L929, 10% FBS, 2 mM L-glutamine and 1 mM sodium pyruvate for 7 days. BMDMs were seeded and left unstimulated or stimulated with IFN-γ (25ng/mL, PeproTech) overnight and then infected with Mtb at an MOI of 5. After 4 h incubation, macrophages were washed twice with PBS to remove extracellular bacteria and incubated in fresh complete medium with or without IFNγ. In some conditions, bafilomycin A (100ng/mL, Sigma) or Q203 (at specified concentrations) was added. Cells were lysed with 1% Saponin/PBS (Sigma) at 120 h after infection and then plated on 7H10-OADC plates in serial dilutions. CFUs were counted after 3 weeks of incubation at 37°C.

Flow cytometry

For flow cytometry, BMDMs pretreated with or without IFN-γ were infected with Live/Dead reporter Mtb strains. At day 3 post-infection, tetracycline (500 ng/ml) was added to medium. Macrophages were harvested after 24 hours tetracycline addition and fixed with 1% PFA for 45 minutes, then run on an LSR II flow cytometer.

Acid sensitivity assays

Mtb strains in log-phase were wash twice with PBST (PBS + 0.05% Tween 80) and once with respective pH-adjusted media. For the 96-well plate assays, wells with 7H9-Tyloxapol-7.4, 7H9-Ty-6.0, 7H9-Ty-5.5, 7H9-Ty-5.0 and 7H9-Ty-4.5 were inoculated to a starting optical density at 600 nm (OD600) of 0.01. Inkwells with 10mL of 7H9-Tyloxapol-7.4, 7H9-Ty-6.2, and 7H9-Ty-5.7 were inoculated to a starting optical density at 600 nm (OD600) of 0.1. Citrate phosphate buffer or 2N NaOH were added to 7H9 medium containing oleic acid-albumin-dextrose-catalase (OADC, Becton, Dickinson), 0.2% glycerol, and 0.02% Tyloxapol until the desired pH was achieved. After a week in culture, the pH of the media was measured to ensure it was properly buffered. The pH 7 media was between pH 6.75–6.91, pH 6.2 media was between 6.23–6.30, and pH 5.7 media was between pH 5.60–5.70. There was no significant difference in media pH between H37Rv and ΔcydA cultures. In specified conditions, DMSO-reconstituted Q203 (gifted from Professor Barry Clifton, MedChemExpress Cat. No:HY-101040) was added to cultures at the indicated concentrations. The Syngery HXT microplate reader was used to measure daily OD600 of 100uL aliquots in a 96 well plate.

In vitro growth CFU assays

During in vitro assays, samples of each 10mL were collected on day 0, 3 (only in the Q203 assay), and 6. Samples were frozen in 15% glycerol. At the time of plating, samples were thawed and washed twice with PBST. Serial dilutions were done in PBST and plated on Middlebrook 7H10 agar supplemented with OADC (Fisher Scientific Cat. No. B12351) and glycerol. Plates for ΔcydA and ΔcydA::ABDC contained hygromycin (50ug/mL) or hygromycin (50ug/mL) + zeocin (25ug/mL), respectively. Plates were incubated at 37°C for 3 weeks before counting CFU.

Extracellular flux analysis

The OCR of Mtb bacilli adhered to the bottom of an XF cell culture microplate (Cell-Tak coated) (Seahorse Biosciences), at 2x106 bacilli per well, were measured using a XF96 Extracellular Flux Analyser (Seahorse Biosciences)[7]. All XF assays were carried out in unbuffered 7H9 media (pH 7.4 or pH 4.5 for acidic conditions) without a carbon source. Basal OCR was measured for ~ 25 min before the addition of compounds through the drug ports of the sensor cartridge. After media or Q203 addition (300x MIC50 0.9uM) or BDQ (300x MIC50 16.2uM), OCR was measured for ~ 40 min, followed by the addition of the uncoupler carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (2 μM) and the OCR measured for a further ~20 min. All OCR Figures indicate the approximate point of each addition as dotted lines. OCR data points are representative of the average OCR during 4 min of continuous measurement in the transient microchamber, with the error being calculated from the OCR measurements taken from at least three replicate wells by the Wave Desktop 2.2 software (Seahorse Biosciences). The microchamber is automatically re-equilibrated between measurements through the up and down mixing of the probes in the wells of the XF cell culture microplate.

MIC assay

Log-phase H37Rv was washed twice with PBS + 0.02% tyloxapol and used to inoculate 10mL cultures of 7H9-Ty-7.0, 7H9-Ty-6.5, and 7H9-Ty-5.5 to an OD600 of 0.02. As stated before, media pH was achieved by the addition of citrate-phosphate buffer or 2N NaOH. To determine the MIC of Q203 (Cat. No. HY-101040, MedChemExpress), 3-fold serial dilutions from 24nM to 0.3 nM were performed at pH 7.0, 6.5, and 5.5 with a vehicle (DMSO) control. Cultures were incubated at 37°C in inkwells with shaking. The Syngery HXT microplate reader was used to measure daily OD600 of 100uL aliquots in a 96 well plate. The MIC values were calculated on day 6 of growth using nonlinear regression analysis.

Statistical analyses

Statistical tests and the number of replicate experiments performed are noted in each figure legend. For ANOVA analyses, the specific post-test used in each figure panel, was chosen based on the experimental design. Dunnet’s post-test was used for comparing multiple experimental conditions to a single control sample. Sidak’s post-test was used for comparing multiple pre-defined comparisons. Tukey’s post-test was used if all samples were compared to each other.

Data Availability

All relevant data are within the manuscript.

Funding Statement

This work was supported by the National Institutes of Health (grant AI32130 to C.M.S.), National Natural Science Foundation of China (grant 82072252 to Y.C.), and the Arnold and Mabel O. Beckman Foundation (A.J.O.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NIH: https://www.nih.gov/ Beckman Foundation: https://www.beckman-foundation.org/.

References

  • 1.Organization WH. Global tuberculosis report 2018. 2018.
  • 2.Beites T, O’Brien K, Tiwari D, Engelhart CA, Walters S, Andrews J, et al. Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development. Nat Commun. 2019;10(1):4970. Epub 2019/11/02. doi: 10.1038/s41467-019-12956-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Foo CS, Lupien A, Kienle M, Vocat A, Benjak A, Sommer R, et al. Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis. mBio. 2018;9(5). Epub 2018/10/12. doi: 10.1128/mBio.01276-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kalia NP, Hasenoehrl EJ, Ab Rahman NB, Koh VH, Ang MLT, Sajorda DR, et al. Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection. Proc Natl Acad Sci U S A. 2017;114(28):7426–31. Epub 2017/06/28. doi: 10.1073/pnas.1706139114 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med. 2013;19(9):1157–60. Epub 2013/08/06. doi: 10.1038/nm.3262 . [DOI] [PubMed] [Google Scholar]
  • 6.de Jager VR, Dawson R, van Niekerk C, Hutchings J, Kim J, Vanker N, et al. Telacebec (Q203), a New Antituberculosis Agent. N Engl J Med. 2020;382(13):1280–1. Epub 2020/03/27. doi: 10.1056/NEJMc1913327 . [DOI] [PubMed] [Google Scholar]
  • 7.Lamprecht DA, Finin PM, Rahman MA, Cumming BM, Russell SL, Jonnala SR, et al. Turning the respiratory flexibility of Mycobacterium tuberculosis against itself. Nature Communications. 2016;7:12393. doi: 10.1038/ncomms12393https://www.nature.com/articles/ncomms12393#supplementary-information. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Borisov VB, Gennis RB, Hemp J, Verkhovsky MI. The cytochrome bd respiratory oxygen reductases. Biochim Biophys Acta. 2011;1807(11):1398–413. Epub 2011/07/16. doi: 10.1016/j.bbabio.2011.06.016 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Cook GM, Cruz-Ramos H, Moir AJ, Poole RK. A novel haem compound accumulated in Escherichia coli overexpressing the cydDC operon, encoding an ABC-type transporter required for cytochrome assembly. Arch Microbiol. 2002;178(5):358–69. Epub 2002/10/11. doi: 10.1007/s00203-002-0467-6 . [DOI] [PubMed] [Google Scholar]
  • 10.Moosa A, Lamprecht DA, Arora K, Barry CE 3rd, Boshoff HIM, Ioerger TR, et al. Susceptibility of Mycobacterium tuberculosis Cytochrome bd Oxidase Mutants to Compounds Targeting the Terminal Respiratory Oxidase, Cytochrome c. Antimicrob Agents Chemother. 2017;61(10). Epub 2017/08/02. doi: 10.1128/AAC.01338-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Lindqvist A, Membrillo-Hernandez J, Poole RK, Cook GM. Roles of respiratory oxidases in protecting Escherichia coli K12 from oxidative stress. Antonie Van Leeuwenhoek. 2000;78(1):23–31. Epub 2000/10/04. doi: 10.1023/a:1002779201379 . [DOI] [PubMed] [Google Scholar]
  • 12.D’Mello R, Hill S, Poole RK. The cytochrome bd quinol oxidase in Escherichia coli has an extremely high oxygen affinity and two oxygen-binding haems: implications for regulation of activity in vivo by oxygen inhibition. Microbiology. 1996;142 (Pt 4):755–63. Epub 1996/04/01. doi: 10.1099/00221287-142-4-755 . [DOI] [PubMed] [Google Scholar]
  • 13.Lu P, Heineke MH, Koul A, Andries K, Cook GM, Lill H, et al. The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress. Sci Rep. 2015;5:10333. Epub 2015/05/28. doi: 10.1038/srep10333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Aung HL, Berney M, Cook GM. Hypoxia-activated cytochrome bd expression in Mycobacterium smegmatis is cyclic AMP receptor protein dependent. J Bacteriol. 2014;196(17):3091–7. Epub 2014/06/18. doi: 10.1128/JB.01771-14 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kana BD, Weinstein EA, Avarbock D, Dawes SS, Rubin H, Mizrahi V. Characterization of the cydAB-encoded cytochrome bd oxidase from Mycobacterium smegmatis. J Bacteriol. 2001;183(24):7076–86. Epub 2001/11/22. doi: 10.1128/JB.183.24.7076-7086.2001 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Zhang YJ, Reddy MC, Ioerger TR, Rothchild AC, Dartois V, Schuster BM, et al. Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing. Cell. 2013;155(6):1296–308. Epub 2013/12/10. doi: 10.1016/j.cell.2013.10.045 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Shi L, Sohaskey CD, Kana BD, Dawes S, North RJ, Mizrahi V, et al. Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc Natl Acad Sci U S A. 2005;102(43):15629–34. Epub 2005/10/18. doi: 10.1073/pnas.0507850102 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med. 2003;198(5):705–13. Epub 2003/09/04. doi: 10.1084/jem.20030205 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Husain M, Bourret TJ, McCollister BD, Jones-Carson J, Laughlin J, Vazquez-Torres A. Nitric oxide evokes an adaptive response to oxidative stress by arresting respiration. J Biol Chem. 2008;283(12):7682–9. Epub 2008/01/17. doi: 10.1074/jbc.M708845200 . [DOI] [PubMed] [Google Scholar]
  • 20.Ohkuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A. 1978;75(7):3327–31. Epub 1978/07/01. doi: 10.1073/pnas.75.7.3327 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.MacMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science. 2003;302(5645):654–9. Epub 2003/10/25. doi: 10.1126/science.1088063 . [DOI] [PubMed] [Google Scholar]
  • 22.Murphy KC, Nelson SJ, Nambi S, Papavinasasundaram K, Baer CE, Sassetti CM. ORBIT: a New Paradigm for Genetic Engineering of Mycobacterial Chromosomes. mBio. 2018;9(6). Epub 2018/12/13. doi: 10.1128/mBio.01467-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Martin CJ, Booty MG, Rosebrock TR, Nunes-Alves C, Desjardins DM, Keren I, et al. Efferocytosis is an innate antibacterial mechanism. Cell Host Microbe. 2012;12(3):289–300. Epub 2012/09/18. doi: 10.1016/j.chom.2012.06.010 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ehrt S, Schnappinger D, Bekiranov S, Drenkow J, Shi S, Gingeras TR, et al. Reprogramming of the macrophage transcriptome in response to interferon-gamma and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. J Exp Med. 2001;194(8):1123–40. Epub 2001/10/17. doi: 10.1084/jem.194.8.1123 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A. 1997;94(10):5243–8. Epub 1997/05/13. doi: 10.1073/pnas.94.10.5243 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Mason MG, Shepherd M, Nicholls P, Dobbin PS, Dodsworth KS, Poole RK, et al. Cytochrome bd confers nitric oxide resistance to Escherichia coli. Nat Chem Biol. 2009;5(2):94–6. Epub 2008/12/26. doi: 10.1038/nchembio.135 . [DOI] [PubMed] [Google Scholar]
  • 27.Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, et al. Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. The Journal of experimental medicine. 2003;198(5):693–704. doi: 10.1084/jem.20030846 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Vandal OH, Pierini LM, Schnappinger D, Nathan CF, Ehrt S. A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis. Nat Med. 2008;14(8):849–54. Epub 2008/07/22. doi: 10.1038/nm.1795 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Berney M, Hartman TE, Jacobs WR Jr. A Mycobacterium tuberculosis cytochrome bd oxidase mutant is hypersensitive to bedaquiline. mBio. 2014;5(4):e01275–14. Epub 2014/07/17. doi: 10.1128/mBio.01275-14 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Jones-Carson J, Husain M, Liu L, Orlicky DJ, Vazquez-Torres A. Cytochrome bd-Dependent Bioenergetics and Antinitrosative Defenses in Salmonella Pathogenesis. mBio. 2016;7(6). Epub 2016/12/22. doi: 10.1128/mBio.02052-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Jones SA, Chowdhury FZ, Fabich AJ, Anderson A, Schreiner DM, House AL, et al. Respiration of Escherichia coli in the mouse intestine. Infect Immun. 2007;75(10):4891–9. Epub 2007/08/19. doi: 10.1128/IAI.00484-07 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Corbett D, Goldrick M, Fernandes VE, Davidge K, Poole RK, Andrew PW, et al. Listeria monocytogenes Has Both Cytochrome bd-Type and Cytochrome aa 3-Type Terminal Oxidases, Which Allow Growth at Different Oxygen Levels, and Both Are Important in Infection. Infect Immun. 2017;85(11). Epub 2017/08/16. doi: 10.1128/IAI.00354-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Dhar N, McKinney JD. Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice. Proc Natl Acad Sci U S A. 2010;107(27):12275–80. Epub 2010/06/23. doi: 10.1073/pnas.1003219107 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wiseman B, Nitharwal RG, Fedotovskaya O, Schafer J, Guo H, Kuang Q, et al. Structure of a functional obligate complex III2IV2 respiratory supercomplex from Mycobacterium smegmatis. Nat Struct Mol Biol. 2018;25(12):1128–36. Epub 2018/12/07. doi: 10.1038/s41594-018-0160-3 . [DOI] [PubMed] [Google Scholar]
  • 35.Safarian S, Rajendran C, Muller H, Preu J, Langer JD, Ovchinnikov S, et al. Structure of a bd oxidase indicates similar mechanisms for membrane-integrated oxygen reductases. Science. 2016;352(6285):583–6. Epub 2016/04/30. doi: 10.1126/science.aaf2477 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Bansal R, Anil Kumar V, Sevalkar RR, Singh PR, Sarkar D. Mycobacterium tuberculosis virulence-regulator PhoP interacts with alternative sigma factor SigE during acid-stress response. Mol Microbiol. 2017;104(3):400–11. Epub 2017/02/01. doi: 10.1111/mmi.13635 . [DOI] [PubMed] [Google Scholar]
  • 37.Rohde KH, Abramovitch RB, Russell DG. Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues. Cell Host Microbe. 2007;2(5):352–64. Epub 2007/11/17. doi: 10.1016/j.chom.2007.09.006 . [DOI] [PubMed] [Google Scholar]
  • 38.Tan S, Sukumar N, Abramovitch RB, Parish T, Russell DG. Mycobacterium tuberculosis responds to chloride and pH as synergistic cues to the immune status of its host cell. PLoS Pathog. 2013;9(4):e1003282. Epub 2013/04/18. doi: 10.1371/journal.ppat.1003282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Lu X, Williams Z, Hards K, Tang J, Cheung CY, Aung HL, et al. Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis. ACS Infect Dis. 2019;5(2):239–49. Epub 2018/11/30. doi: 10.1021/acsinfecdis.8b00225 . [DOI] [PubMed] [Google Scholar]
  • 40.van der Westhuyzen R, Winks S, Wilson CR, Boyle GA, Gessner RK, Soares de Melo C, et al. Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration. J Med Chem. 2015;58(23):9371–81. Epub 2015/11/10. doi: 10.1021/acs.jmedchem.5b01542 . [DOI] [PubMed] [Google Scholar]
  • 41.Hards K, Robson JR, Berney M, Shaw L, Bald D, Koul A, et al. Bactericidal mode of action of bedaquiline. J Antimicrob Chemother. 2015;70(7):2028–37. Epub 2015/03/11. doi: 10.1093/jac/dkv054 . [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Michael R Wessels, Helena Ingrid Boshoff

9 Sep 2020

Dear Dr. Sassetti,

Thank you very much for submitting your manuscript "Host immunity increases Mycobacterium tuberculosis reliance on cytochrome bd oxidase" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

The reviewers raise some comments that can easily be addressed (defining 100% OCR for the strains, etc). However, some concerns require additional work including defining actual CFU for critical experiments (CFU analysis for strains grown at low pH in presence/absence of Q203), analysis of the survival of the cyd mutant at low pH in the presence/absence of Q203 and preferably including the complemented strain in the flux analysis.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Helena Ingrid Boshoff

Associate Editor

PLOS Pathogens

Michael Wessels

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

The reviewers raise some comments that can easily be addressed (defining 100% OCR for the strains, etc). However, some concerns require additional work including defining actual CFU for critical experiments (CFU analysis for strains grown at low pH in presence/absence of Q203), analysis of the survival of the cyd mutant at low pH in the presence/absence of Q203 and preferably including the complemented strain in the flux analysis.

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: Elucidating the role of the alternate branch of the aerobic electron transport chain in mycobacteria terminating in cytochrome bd oxidase has been a topic of considerable interest particularly in light of the discovery of QcrB as a vulnerable TB drug target and subsequent clinical development of Q203 as a new drug candidate. While there is abundant evidence of bd oxidase upregulation in mycobacteria in response to disruption of the main cytochrome bc1-aa3-terminating branch of the ETC, the specific cellular function/s served by the bd oxidase in the physiology of Mtb has remained elusive. This problem has been further compounded by discrepant findings on the impact of inactivating mutations in the cydABDC gene cluster on growth and persistence of Mtb during mouse infection with one earlier study revealing a persistence defect in late-stage infection, but others showing no discernible effect.

In this manuscript, the authors re-visit this question and demonstrate a role for the bd oxidase in resisting the host adaptive immune response via an atypical IFNg-dependent mechanism which does not rely on reactive nitrogen or oxygen radicals to inhibit the bd oxidase, but is manifest instead at low pH. In a significant advance, they establish a role for the bd oxidase in respiration under acidic conditions and accordingly show potentiation of anti-TB activity of Q203 at low pH. This is a clearly written manuscript that describes some important results of general interest.

Reviewer #2: The cytochrome bd oxidase is a bacteria-specific terminal oxidase involved in microaerophilic respiration and resistance to oxidative stress in several bacteria, including Mycobacterium tuberculosis. In this article, the author reports on the involvement of the cytochrome bd oxidase in resistance to host immunity in macrophages and in a mouse model of tuberculosis infection. Using an H37Rv �cydC strain, a series of experiments was conducted to demonstrate the requirement of the bd oxidase for optimal growth at acidic pH, for viability in IFN-g activated macrophages (in a NOS2- and Cybb-independent manner) and for respiration at low pH. The article has some merits but is to some extent difficult to read and evaluate given the lack of experimental details, heavy reliance on data normalization and -on few occasions- issues with data analysis. The rational for using several statistical methods throughout the study should be explained.

Reviewer #3: The paper by Sassetti and colleagues reports the role of cytochrome bd (cyd) of M. tuberculosis in resisting the adaptive immune response. The molecular basis for this adaptation was the role of cytochrome bd in protecting M. tuberculosis from the acidic pH of the IFN�-activated macrophages. The authors demonstrate that oxygen consumption by the cyd mutant is decreased at low pH because the bcc-aa3 proton-pumping complex is inhibited by an unknown mechanism. The manuscript is important because it again validates the respiratory oxidases as essential targets in TB drug development.

The paper is well written and the data presented in an easy to follow structure. However, the OCR work is a little disappointing as crucial pieces of information are missing that this referee requires to make a suitable recommendation.

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: Line 185-187 and Fig. 4C and D. These refer to a ΔcydAB mutant, however this strain is not described in the Experimental Methods (line 264). A complemented derivative of the cydAB (or cydA?) mutant used in the flux analysis experiments shown in Fig. 4C and 4D must be included to confirm that the effect observed is attributable specifically to abrogation of bd oxidase function.

Reviewer #2: Figure 1

-Line 120/121: is the statement that addition of IFN-g significantly reduced the number of cells harboring live H37Rv supported by statistics (Fig 1b)?

- Mycobacterial viability in macrophages was monitored using a GFP/RFP reporter system, or CFU determination. FACS was used to determine the number of macrophages containing live bacteria (GFP+/RFP+) or dead bacteria (GFP+). Is the approach able to detect a cell containing both live and dead bacteria ? if not, this limitation should be discussed.

- line 125. The statement that the viability recorded with the report genes system (Fig 1b) correlates with CFU determination (Fig 1c) is not totally accurate since some statistical differences observed with the reporter genes were not confirmed by CFU determination. Please comment.

- The use of the ANOVA with Sidak post-test to analyze panel b and c, and the Dunnett’s multiple comparisons test for c need to be justified. What was the requirement to use ANOVA and the need for the Sidak post-test. How many times were the experiments repeated. Statistic should be applied to compared other conditions in panel d (e.g. H37Rv unstimulated vs H37Rv IFN-g stimulated or DcydD vs DcydD:cydABDC – both IFN-g activated).

- The need to normalize the results in the panel c & d should also be explained, why not presenting the CFU numbers instead of normalized values?

If the results are presented “as percent survival relative to untreated”, what does the standard deviation reflect in the untreated control groups?

Figure 2

- Co-infection was an excellent idea to compare the fitness of the cydA-deficient strain in animals. Few experimental details should be added to support the findings: inoculum size, number of animals per group, how many times the experiments were repeated, statistical method used. The bacterial load early after infection (e.g. 24 hours) should be shown to ensure that the implementation of both strains was in a similar range. If those data are not available, the enumeration of the ratio cydA-deficient/H37Rv in the inoculum would address this concern.

- A limitation of the study is the lack of one late time point to enhance the confidence that the differences (which are at best 5-fold reduction) at day 30 are robust.

- Lanbo Shi (PNAS 2005) reported that a H37Rv DcydC multiplied well in NOS2-/- mice, whereas this study suggests an attenuation phenotype. What could explain the difference with this previous report ?

Figure 3

- My main concern on this part of the work is the use of several assay formats to monitor growth. The assay in Fig 3a-b was done in 96 well plates (I assume the medium was 7H9-OADC-tyloxapol). This assay format may induce early oxygen depletion that could explain the requirement of the cyt-bd for optimum growth. The growth does not seem to be logarithmic, suggesting that the conditions are sub-optimum for growth.

- Growth rate should be calculated to confirm (using statistics) that the cydA KO multiplies at a slower rate at acidic pH. The pH of the culture broth media should be monitor overtime since the use of a phosphate buffer may not be appropriate to maintain the pH at 4.5.

- To rule out the influence of oxygen, the growth kinetics should be repeated at a higher constant oxygen tension (for instance in roller bottles or under slow agitation) to confirm the results. Comparing the results from Fig 3a-b with Fig 3c is not possible since the complementation studied was performed in a different assay format, and at only one time point. Fig 3c should be repeated in the same format as in Fig 3a-b and growth should be recorded at regular time interval to derive a growth rate.

- The macrophage experiments look convincing but should be confirmed (maybe in wt or NOS2-/- macrophages only) by CFU determination. It is a bit of as stretch to claim that the growth rescue of the cydA KO strain is a direct consequence of the increase in the pH of the phagosome: Bafilomycin A1 has multiple effects on the phagosome maturation that could explain the rescue. Please discuss the limitation of Bafilomycin A1.

Figure 4

- I have some difficulties understanding the design of the respirometry experiments. What seem to have been measured and discussed is not the effect of the pH on OCR, but the adaptive response after treatment with Q203.

- Instead of the % OCR (that seems to indicate that the baseline respiratory rates were normalized), it would be more appropriate to present the data in absolute unit (pmol O2 consumed/min). In additional experiments, the bacteria should also be pre-incubated at pH 7.4 and 4.5 for 30 to 60 min before OCR recording (in absolute unit) to give a better reflection of the effect of low pH on mycobacterial respiration. Alternatively, OCR recording could be extended to few hours.

- The statement “At pH 4.5, Q203-treated cells displayed an even higher OCR than at neutral pH, potentially indicating further inhibition of the cytochrome bc1/aa3 complex and increased reliance on cytochrome bd” is not accurate. It is not the OCR that is higher at low pH, but the extend of the OCR deregulation induced by Q203, which is a phenomenon not fully understood. The use of bedaquiline as a control would be a good addition.

- The interpretation of the results obtained with the cydA-deficient strain (lines 186-188) is peculiar. The mutant is already in a medium at either pH of 7.4 or 4.5. Injecting few ul of the same medium at the same pH should not trigger any change in OCR. I do not really follow how this observation could indicate that the bc1-aa3 is preferentially reduced under these conditions (lines 189-190). Was this experiment repeated more than once?

- As presented and analyzed, the respiratory experiments do not seem to support the conclusion that Mtb reliance on the cyt-bd is higher a low pH.

- The observation that Q203 has a lower MIC at pH 5.5 is interesting. For a direct comparison between the OCR and the MIC results, it would be nice to run both experiments at a similar pH.

- panel E. By default, it is a better practice to plot the raw OD600 values, what is the justification to normalize the values? Even if the bacteria multiply at a reduced rate at low pH, MIC50 can still be determined accurately. I would like to see few controls such as bedaquiline and rifampin to ensure that the shift in MIC is specific to Q203. To facilitate the experimental design, I would advise to use a microplate format (instead of the larger 10 ml volumes) and 2-fold drug dilution (8 points) to derive an accurate MIC50.

- There are few inconsistencies between the figure legends and the method section that need to be fixed. For instance, it is not clear if Q203 was used at 10 nM or at 900 nM in the respiratory experiments.

Reviewer #3: Specific comments for authors:

1. Fig 1A – did OD600 mirror cell viability (CFU) given the culture would have been experiencing hypoxia at day 12?

2. Did the authors perform an additional control for Fig. 1D by transforming CydABDC into the wild-type strain?

3. Fig. 3: please report the growth rate as a function of pH – calculated from logscale plots. The cydA mutant looks to be growing faster than WT? What is the actual difference here? In each of the pH values tested what was the final pH of the culture measured at 5 h? Does the pH increase or remain relatively constant? Same comment for Fig. 3C – what was growth rate?

4. Fig. 3: What does cell survival look like as a function of external pH? Do the cells also die at acidic pH and if so what is the mechanism of cell death – the obvious explanation is a defect in intracellular pH homeostasis. Can the authors comment on this?

5. Fig. 4: to make sense of this figure I need to know what 100% OCR is for the WT and CydAB mutant – are the rates the same? I need to see the data so I can make sense of the interpretation. Same comment applies to OCR at pH 7.4 and 4.5 –for wild-type and cyd what are the actual rates for 100% OCR?

6. Fig4E: why do the cells become more inhibited by Q203 at acidic pH if CydAB+ is still present? What does this data look like in the cyd mutant? Does Q203 (bacteriostatic) become bactericidal against the wild-type at acidic pH – this is an essential experiment.

7. Discussion page 9: why does low pH preferentially inhibit the bcc1-aa3 complex? You clearly show that the cyd mutant can still respire at acidic pH – need to know what the actual rate is in Fig. 4D to make any rational judgements.

8. Lines 78-80: cyd mutants of M. smegmatis are also hypersusceptible to bedaquiline and cydAB is induced by BDQ – cite Hards et al. J Antimicrob Chemother 2015; 70: 2028–2037 (reference 35 covers M. tb only)

9. Paper by the group of Rubin (ref 27) needs to be given a little more kudos for identifying the essential role for the cyd operon at acidic pH. Add to introduction.

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: 1. Figure 1B and 1C, and text describing the experiments shown in this figure (lines 111-133). These figures show the statistical significance of comparisons between WT and ΔcydA strains. However, the more informative comparisons are between WT or mutant +/- IFNγ rather than between WT vs. mutant under a given condition (+/- IFNγ). Therefore, does either assay (Live/Dead or CFU) support the claim that the: “In wildtype BMDMs, addition of IFNg significantly reduced the number of cells harbouring live H37Rv and ΔcydA bacteria (Figure 1B)”, and if so, at what level of significance? Likewise, for the statement: “The CFU assay also showed that IFNγ treatment reduced the viability of H37Rv in a Nos2-dependent and Cybb-independent manner….”.

2. Line 82. Dhar & McKinney (PMC2901468) identified a transposon mutant in cydC in a screen for Mtb mutants that show accelerated clearance by INH in mice in a manner “dependent on environmental changes imposed by the IFN-γ-mediated immune response”. This paper is highly relevant to the work described in this study and must therefore be cited, and its implications for the work reported here discussed.

3. The authors attribute their ability to discern a persistence defect in IFNγ-competent mice to the fact that the experiment was done as a co-infection of WT and cydA mutant strains; even then, the persistence defect at day 30 is very modest (Fig. 2B). Is this due to the fact that in a competition assay, the cydA mutant has a competitive disadvantage against WT owing to an impaired ability to utilise (limited) oxygen during chronic infection? To broaden its appeal, the manuscript would also benefit from a fuller explanation of the implications of the findings for Mtb pathogenesis, including in the context of all the published literature. For example, what do the results reported here mean in terms of acidic (and hypoxic?) microenvironments in different mouse infection models? How does this differ in other animal models, in particular, NHPs? Can the authors speculate on why treatment of Mtb-infected marmosets with a bc1-aa3 inhibitor gave rise to cavitation, as reported by Beites et al.?

4. Line 79: Kana et al. (PMC95555) were the first to demonstrate induction of the cydABDC operon and a competitive growth disadvantage of a bd oxidase of M. smegmatis under hypoxia. This reference should be cited.

5. Line 187 - Reference is made to “green line and bar” but these are not shown.

6. Line 116: Replace "Figure 1B-C by "Figure 1B"

Reviewer #2: -

Reviewer #3: (No Response)

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here on PLOS Biology: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see http://journals.plos.org/plospathogens/s/submission-guidelines#loc-materials-and-methods

Decision Letter 1

Michael R Wessels, Helena Ingrid Boshoff

12 Jul 2021

Dear Dr. Sassetti,

We are pleased to inform you that your manuscript 'Host immunity increases Mycobacterium tuberculosis reliance on cytochrome bd oxidase' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Helena Ingrid Boshoff

Associate Editor

PLOS Pathogens

Michael Wessels

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************************************************

The authors have addressed all important concerns. This work is an important contribution to the field's understanding of the relative contribution of the different terminal oxidases to survival under different in vivo conditions.

Reviewer Comments (if any, and for reference):

Acceptance letter

Michael R Wessels, Helena Ingrid Boshoff

22 Jul 2021

Dear Dr. Sassetti,

We are delighted to inform you that your manuscript, "Host immunity increases Mycobacterium tuberculosis reliance on cytochrome bd oxidase," has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript.


    Articles from PLoS Pathogens are provided here courtesy of PLOS

    RESOURCES